# Merus (stock symbol: MRUS) Logo in transparent PNG and SVG formats

## Merus Logo large

### Merus Logo large Download PNG (25.25 KB)

![Merus Logo large Download PNG (25.25 KB)](/img/orig/MRUS_BIG-db8e13be.png)

### Merus Logo large Download SVG (3.13 KB)

![Merus Logo large Download SVG (3.13 KB)](/img/orig/MRUS_BIG-38c9aa8b.svg)

## Merus Logo icon format

### Merus Logo icon format Download PNG (37.78 KB)

![Merus Logo icon format Download PNG (37.78 KB)](/img/orig/MRUS-9d118bf6.png)

### Merus Logo icon format Download SVG (866 Bytes)

![Merus Logo icon format Download SVG (866 Bytes)](/img/orig/MRUS-425ca100.svg)

## About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

1. Website domain: merus.nl
2. Marketcap: $0.88 Billion USD


## Categories
- [x] ðŸ‡³ðŸ‡± Netherland
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
